Palvella Therapeutics, Inc. financial data

Symbol
PVLA on Nasdaq
Industry
Pharmaceutical Preparations
Location
125 Strafford Ave, Suite 360, Wayne, PA
State of incorporation
NV
Fiscal year end
December 31
Former names
PIERIS PHARMACEUTICALS, INC. (to 12/12/2024), Marika Inc. (to 12/18/2014)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 179 % -27%
Debt-to-equity 1.29K % +79.9%
Return On Assets -42.7 % -235%
Operating Margin 57 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11M shares -88.9%
Common Stock, Shares, Outstanding 11M shares +522%
Entity Public Float 9.2M USD -18%
Common Stock, Value, Issued 11K USD
Weighted Average Number of Shares Outstanding, Basic 2.23M shares +25.7%
Weighted Average Number of Shares Outstanding, Diluted 1.32M shares +6.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.35M USD -97.1%
Research and Development Expense -17M USD -131%
General and Administrative Expense 5.94M USD +93.2%
Operating Income (Loss) -14.1M USD -18.8%
Net Income (Loss) Attributable to Parent -17.4M USD -193%
Earnings Per Share, Basic -7.83 USD/shares -458%
Earnings Per Share, Diluted -2.19 USD/shares +74.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 83.6M USD +1037%
Cash, Cash Equivalents, and Short-term Investments 19.4M USD -56.7%
Accounts Receivable, after Allowance for Credit Loss, Current 358K USD
Assets, Current 88.2M USD +1069%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 88.2M USD +1069%
Accounts Payable, Current 4.59M USD +390%
Employee-related Liabilities, Current 3.07M USD +1656%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 12M USD +410%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD
Liabilities 25.6M USD +124%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3K USD
Retained Earnings (Accumulated Deficit) -93.7M USD -22.8%
Stockholders' Equity Attributable to Parent 62.6M USD
Liabilities and Equity 88.2M USD +1069%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7M USD +36.4%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 9M USD -24.4%
Common Stock, Shares Authorized 200M shares +2129%
Common Stock, Shares, Issued 11M shares +522%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.69M USD +52.5%
Deferred Tax Assets, Valuation Allowance 93.3M USD +482%
Deferred Tax Assets, Gross 93.3M USD +482%
Operating Lease, Liability 12.3M USD +0.62%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -17.4M USD -197%
Lessee, Operating Lease, Liability, to be Paid 18.4M USD -3.37%
Property, Plant and Equipment, Gross 26.7M USD +3.93%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.09M USD +7.91%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.09M USD +7.91%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.14M USD -10.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.09M USD +7.91%
Deferred Tax Assets, Operating Loss Carryforwards 82M USD +793%
Preferred Stock, Shares Issued 15.6K shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.09M USD +7.91%
Operating Lease, Payments 700K USD -68.2%
Additional Paid in Capital 156M USD +8499%
Preferred Stock, Shares Outstanding 15.6K shares
Depreciation, Depletion and Amortization 605K USD -28.4%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%